Authorized purpose: Aids clinicians and radiologists reviewing 2D X-ray radiographs by detecting, localizing, and characterizing fractures across the FDA-listed appendicular, hip/pelvis, clavicle, and thorax/rib examinations, and by detecting elbow joint effusion on lateral elbow or forearm views in children/adolescents and adults; results are not standalone clinical decisions.
Evidence status: each field states its source quality, applicability, and review date. Research pending, information not established, and vendor documentation pending remain distinct outcomes.
Product overview
Start with the essentials
Authorized purpose: Aids clinicians and radiologists reviewing 2D X-ray radiographs by detecting, localizing, and characterizing fractures across the FDA-listed appendicular, hip/pelvis, clavicle, and thorax/rib examinations, and by detecting elbow joint effusion on lateral elbow or forearm views in children/adolescents and adults; results are not standalone clinical decisions.
Overview status: Source-reviewed overview
What does this software do?Authorized purpose: Aids clinicians and radiologists reviewing 2D X-ray radiographs by detecting, localizing, and characterizing fractures across the FDA-listed appendicular, hip/pelvis, clavicle, and thorax/rib examinations, and by detecting elbow joint effusion on lateral elbow or forearm views in children/adolescents and adults; results are not standalone clinical decisions.
Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: MSK Input: 2D X-ray radiographs received from DICOM sources; the FDA table supports specified frontal, lateral, oblique, lateral-elbow, ribs-series, and related views for the listed anatomy and age groups.
Who uses it?Intended users: Clinicians authorized to diagnose fractures and/or elbow joint effusions, including primary care, emergency, urgent care, orthopedic clinicians, and radiologists.
What does the software produce?Output: For each processed image, TechCare Trauma reports YES, DOUBT, or NO for each supported finding and can draw solid-line or dotted-line bounding boxes. It also creates a study-level summary image with SUSPECTED, DOUBT, NOT SUSPECTED, or NOT PROCESSED assessment and can return a DICOM Structured Report when configured.
What is its most important limitation?Key limitation: Clinical users retain primary diagnostic and management responsibility. The FDA packet defines DOUBT and YES operating points, returns NOT PROCESSED when all images are outside the indication, and does not establish local PACS compatibility, commercial security, price, or service commitments.
Clinical takeaway
Clinical role: Aids clinicians and radiologists reviewing 2D X-ray radiographs by detecting, localizing, and characterizing fractures across the FDA-listed appendicular, hip/pelvis, clavicle, and thorax/rib examinations, and by detecting elbow joint effusion on lateral elbow or forearm views in children/adolescents and adults; results are not standalone clinical decisions.
Evidence takeaway
Evidence from the reviewed source record: FDA standalone image-level testing used 4,109 adult fracture images, 2,872 pediatric fracture images, 280 adult elbow-joint-effusion images, and 483 pediatric elbow-joint-effusion images. The FDA MRMC study used four external US datasets totaling 769 cases and compared aided with unaided readers.
Clinical details
What this tool is for
Start with the authorized purpose, then verify how it fits your service line and reading workflow.
Exact purpose
Aids clinicians and radiologists reviewing 2D X-ray radiographs by detecting, localizing, and characterizing fractures across the FDA-listed appendicular, hip/pelvis, clavicle, and thorax/rib examinations, and by detecting elbow joint effusion on lateral elbow or forearm views in children/adolescents and adults; results are not standalone clinical decisions.
Clinicians authorized to diagnose fractures and/or elbow joint effusions, including primary care, emergency, urgent care, orthopedic clinicians, and radiologists.
Primary care, emergency medicine, urgent care, specialty care, and radiology review settings; fracture results cover neonates/infants, children/adolescents, and adults, while elbow-effusion results cover children/adolescents and adults.
2D X-ray radiographs received from DICOM sources; the FDA table supports specified frontal, lateral, oblique, lateral-elbow, ribs-series, and related views for the listed anatomy and age groups.
For each processed image, TechCare Trauma reports YES, DOUBT, or NO for each supported finding and can draw solid-line or dotted-line bounding boxes. It also creates a study-level summary image with SUSPECTED, DOUBT, NOT SUSPECTED, or NOT PROCESSED assessment and can return a DICOM Structured Report when configured.
FDA source
Exact FDA submission
Checked 2026-09-07
The packet describes newly generated DICOM series associated with the original study; the output is an aid to clinical review.
Clinical users retain primary diagnostic and management responsibility. The FDA packet defines DOUBT and YES operating points, returns NOT PROCESSED when all images are outside the indication, and does not establish local PACS compatibility, commercial security, price, or service commitments.
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Use these fields to structure a vendor demo, security review, and implementation estimate.
Integration
The FDA packet describes automatic receipt from DICOM sources and return of newly generated result series to specified DICOM destinations, including PACS, VNA, storage platforms, and compatible DICOM viewers; optional DICOM SR can list finding status and area.
FDA source
Exact FDA submission
Checked 2026-09-07
Specific interface versions, routing rules, viewer behavior, and local compatibility remain acceptance-test items.
The reviewed product page uses protected-data language but does not establish the exact deployment's security architecture, retention, access control, audit, or incident-response terms.
Training and support
Vendor documentation pending
Vendor confirmation
Exact FDA submission
Checked 2026-09-07
User training, onboarding, competency, and support commitments were not established for the exact commercial configuration.
Monitoring and change control
Vendor documentation pending
Vendor confirmation
Exact FDA submission
Checked 2026-09-07
Local acceptance testing, production monitoring, drift review, update control, and incident escalation remain to be qualified.
DICOM source and automatic processing
The FDA packet says TechCare Trauma relies on DICOM sources and automatically receives and processes images after network integration without manual intervention.
exact submission · checked 2026-09-07
Validate routing, identifiers, supported views, failure handling, and local compatibility before use.
The packet describes delivery of summary and annotated DICOM series to specified DICOM destinations, including PACS, VNA, storage platforms, and radiological equipment; compatible DICOM viewers can display the results.
Milvue describes the current TechCare Alert configuration as analyzing incoming radiographs, returning localized findings and confidence scores in under 30 seconds, and prioritizing critical cases in the RIS/PACS worklist; its page identifies the US configuration as TechCare Trauma.
product family · checked 2026-09-07
Current family/configuration description, not proof of every feature in the K242171 release.
NICE HTG739 conditionally recommends TechCare Alert for use in NHS urgent care while evidence is generated and calls for local disagreement protocols plus monitoring of accuracy, software failures, downstream referrals, treatment changes, implementation cost, subgroups, and postmarket surveillance.
product family · checked 2026-09-08
English NHS health-technology guidance; not exact K242171 pricing, reimbursement, or US adoption evidence.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA standalone image-level testing used 4,109 adult fracture images, 2,872 pediatric fracture images, 280 adult elbow-joint-effusion images, and 483 pediatric elbow-joint-effusion images. The FDA MRMC study used four external US datasets totaling 769 cases and compared aided with unaided readers.
FDA source
Exact FDA submission
Checked 2026-09-07
The FDA packet reports separate populations and endpoints; these figures are not a pooled performance estimate.
FDA MRMC aided-reader sensitivity increases were reported as +21.8% for adult fracture, +12.7% for adult elbow-joint effusion, +19.9% for pediatric fracture, and +18.2% for pediatric elbow-joint effusion.
FDA source
Exact FDA submission
Checked 2026-09-07
These are reported aided-versus-unaided percentage increases, not standalone sensitivities; the structured metrics retain endpoint and population context.
FDA MRMC aided-reader specificity changes were reported as +1.47% for adult fracture, +1.08% for adult elbow-joint effusion, 0% for pediatric fracture, and +1.43% for pediatric elbow-joint effusion.
FDA source
Exact FDA submission
Checked 2026-09-07
These are reported aided-versus-unaided percentage changes, not standalone specificities.
These are common procurement questions; unknown values remain visible until a source supports them.
Pricing and total cost
Vendor documentation pending
Vendor confirmation
Exact FDA submission
Checked 2026-09-07
No current exact-product price or contract terms were established from the reviewed public sources.
Reimbursement and coding
Research pending
Needs research
Exact FDA submission
Checked 2026-08-31
Determine whether any product-specific CPT/HCPCS pathway exists and separate it from billing for the underlying imaging service.
No product-specific code
NICE HTG739 conditionally recommends TechCare Alert for NHS use during a two-year evidence-generation period, subject to evidence-generation agreements and appropriate regulatory and DTAC approval; this is not a reimbursement determination.
NICE guidance for the NHS in England · England · Effective 2025-01-14
NICE's exploratory model uses GBP 1 per scan and says actual software, implementation, and postmarket costs are uncertain. This is not a vendor quote or US coverage evidence.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Buyer worksheet
Open questions to take to the vendor
Verify security and privacy controls: The reviewed product page uses protected-data language but does not establish the exact deployment's security architecture, retention, access control, audit, or incident-response terms.
Verify training: User training, onboarding, competency, and support commitments were not established for the exact commercial configuration.
Verify pricing and total cost: No current exact-product price or contract terms were established from the reviewed public sources.
Verify reimbursement and coding relevance: Determine whether any product-specific CPT/HCPCS pathway exists and separate it from billing for the underlying imaging service.
Verify local validation and lifecycle monitoring: Local acceptance testing, production monitoring, drift review, update control, and incident escalation remain to be qualified.
Verify recalls and postmarket safety signals: No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-07Last searched
28Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
Stored exact-submission candidate metadata had zero PubMed and ClinicalTrials.gov identifiers. This was metadata screening, not a full paper or registry-record review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, health technology guidance, literature index, trial registry, pubmed, clinical trials, openfda device recall
Sources & history
How this profile was documented
Open the ledger for source dates, scope, and research-record updates.
View source ledger and history9 sources - 3 history items
Assists radiologists and emergency physicians in detecting fractures on DICOM musculoskeletal radiographs for adults and children aged 2 years or older, limited to the FDA-listed...
Opportunistically analyzes standard AP hip or pelvis radiographs in patients aged 50 years and older and issues a report when the estimated femoral-neck BMD is below a preset...
Concurrent-read CADe to assist dentists in detecting specified tooth and jaw anatomy, bone-level landmarks, and root-canal-treated teeth in digital radiographs of permanent teeth...
Modality
X-ray/Radiography
Anatomy
Permanent teeth and jaw/maxillofacial anatomy, including enamel, dentine, pulp, root, mental foramen, inferior alveolar canal, maxillary sinus, cementoenamel junction, crestal bone, and root-canal-treated teeth